Journal article
Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS
Abstract
CONTEXT: Antiresorptive therapy significantly reduces fracture risk in patients with benign bone disease and skeletal-related events (SREs) in patients with bone metastases (BM). Osteonecrosis of the jaw (ONJ) is a rare but severe condition manifested as necrotic bone lesion or lesions of the jaws. ONJ has been linked to the use of potent antiresorptive agents, termed medication-related ONJ (MRONJ).
OBJECTIVE: We aimed to identify the …
Authors
Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body J-J
Journal
The Journal of Clinical Endocrinology & Metabolism, Vol. 107, No. 5, pp. 1441–1460
Publisher
The Endocrine Society
Publication Date
April 19, 2022
DOI
10.1210/clinem/dgab888
ISSN
0021-972X